Search results for: Oncology

OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes

26 October 2016

…and Simona Bianchi (ABPI). The Cancer Drugs Fund (CDF) was created in 2010 to pay for oncology indications that were not approved by the National Institute for Health and Care…

OHE is pleased to appoint two Senior Visiting Fellows: Professor David Parkin and Professor Lou Garrison

5 October 2016

…Evidence Generation Risk-Sharing Agreements Between Pharmaceutical Manufacturers and Payers Personalised Medicine and the Value of Molecular Diagnostics Governance models for real-world evidence The Expanding Value Footprint of Oncology Treatments Lou…

Comparing the Cancer-Specific EORTC-8D and the Generic EQ-5D-3L

4 January 2017

…life gains. Reference: Lorgelly, P.K., Doble, B., Rowen, D. Brazier, J., 2016. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Quality of Life Research. …

Value, Affordability, and Decision Making

…1 December 2025 A global landscape analysis of access to tumour-agnostic therapies Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by targeting molecular alterations regardless of tumour histology. 3…

Capturing the lived experiences of informal care in acute leukemia

20 November 2025

Share this: Download publication Claud Theakston Priscila Radu David Mott Nadine Henderson Samantha Nier Key takeaways Providing informal care to someone living with acute leukemia imposes a severe multidimensional burden,…

Achieving World Class Outcomes in Cancer Treatment

1 July 2011

The speaker for the OHE’s 16th Annual Lecture was Sir Mike Richards, National Clinical Director for Cancer and End of Life Care in England’s Department of Health. In his presentation,…

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

1 January 2022

A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the tumour rather than by…

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations

1 December 2021

Outcome-based payment (OBP) is a flexible payment mechanism linking the price the NHS pays for a medicine to the outcomes it achieves in practice for NHS patients. In 2019 we…

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

8 January 2020

Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin, face significant methodological and…